Results 31 to 40 of about 176 (130)

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

open access: yesAnnals of Oncology, 1999
In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements.Six patients with Ph-negative, BCR-ABL-positive CML were investigated.
D, Seong   +9 more
openaire   +2 more sources

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia

open access: yesBrazilian Journal of Nephrology, 2020
Imatinib, which inhibits tyrosine kinase activity of Bcr-Abl protein, is a standard form of treatment for chronic myeloid leukemia (CML). Through its immunomodulatory effect it affects T cell function in a number of ways.
Abhilash Chandra   +2 more
doaj   +2 more sources

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [PDF]

open access: yesLeukemia, 2001
The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I trial (Druker et al 1999). Combination therapy may increase this proportion. We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea,
J, Topaly, W J, Zeller, S, Fruehauf
openaire   +2 more sources

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

open access: yesThe Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
openaire   +2 more sources

Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction [PDF]

open access: yesBlood, 1989
The Philadelphia (Ph′) chromosome in chronic myelogenous leukemia (CML) results in fusion of the bcr gene and c-abl oncogene, which transcribes into two types of chimeric bcr/abl mRNAs: the L-6 junction and the K-28 junction. By means of a highly sensitive assay, combination of reverse transcription and polymerase chain reaction (RT/PCR), we analyzed ...
M S, Lee   +6 more
openaire   +3 more sources

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2019
JAK2 V617F mutation and BCR-ABL translocation have been considered to be mutually exclusive. However, many cases where both hits coexisted have been reported. We have personally managed a case too. We believe this hybrid entity is underdiagnosed.
Gilbert Bader MD, Bernard Dreiling MD
doaj   +1 more source

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?

open access: yesHematology Reports, 2009
At present, there are no compounds in clinical development in the field of chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) that have been documented to harbor significant activity against the imatinib ...
Giovanni Martinelli   +5 more
doaj   +1 more source

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report

open access: yesLeukemia Research Reports, 2015
Chronic myelogenous leukemia (CML), in the Chronic Phase (CP), is often suspected as a result of a complete blood count (CBC), which shows increased granulocytes, mostly mature including a peak in myelocytes, increased basophils, and rarely blasts and/or
John M. Bennett   +3 more
doaj   +1 more source

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

open access: yesIraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir   +1 more
doaj   +1 more source

Human biomarker navigator

open access: yesiMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy